SCHEMBL13288756

SCHEMBL13288756

Bc1cnn2c(NCCCN(C)C(=O)c3ccoc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 6/20 0.40
▸ CDK2 P24941 5/20 0.40
▸ ABCB1 P08183 2/20 0.39
▸ ABCG2 Q9UNQ0 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ CCR6 P51684 1/20 0.35
▸ BRD4 O60885 1/20 0.33
▸ CCNE1 P24864 1/20 0.32
▸ KLKB1 P03952 1/20 0.32
▸ KLK1 P06870 1/20 0.32
▸ CSNK2A1 P68400 1/20 0.32
▸ HIPK2 Q9H2X6 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ FYN P06241 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13120345 0.91 GSK3B (0.52) GSK3BCDK2ABCB1ABCG2KDM4E
SCHEMBL13288758 0.89 KDM4E (0.42) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288834 0.89 GSK3B (0.42) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13289307 0.88 GSK3B (0.41) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288912 0.87 GSK3B (0.43) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288809 0.86 CDK2 (0.43) GSK3BCDK2BRD4PDE2A
SCHEMBL13288966 0.85 GSK3B (0.40) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288933 0.85 RAB9A (0.41) GSK3BCDK2MAPTRAB9A
SCHEMBL13289036 0.85 ALDH1A1 (0.40) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288863 0.85 CSNK2A1 (0.39) GSK3BCDK2KDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback